Gene Therapy Program, Institute of Human Genetics, Department of Genetics, Cell Biology, and Development, University of Minnesota, Minneapolis, MN 55455, USA.
Hum Gene Ther. 2010 Jul;21(7):865-75. doi: 10.1089/hum.2009.162.
Artemis is a hairpin-opening endonuclease involved in nonhomologous end-joining and V(D)J recombination. Deficiency of Artemis results in radiation-sensitive severe combined immunodeficiency (SCID) characterized by complete absence of T and B cells due to an arrest at the receptor recombination stage. We have generated several lentiviral vectors for transduction of the Artemis sequence, intending to complement the deficient phenotype. We found that transduction by a lentiviral vector in which Artemis is regulated by a strong EF-1alpha promoter resulted in a dose-dependent loss of cell viability due to perturbed cell cycle distribution, increased DNA damage, and increased apoptotic cell frequency. This toxic response was not observed in cultures exposed to identical amounts of control vector. Loss of cell viability was also observed in cells transfected with an Artemis expression construct, indicating that toxicity is independent of lentiviral transduction. Reduced toxicity was observed when cells were transduced with a moderate-strength phosphoglycerate kinase promoter to regulate Artemis expression. These results present a novel challenge in the establishment of conditions that support Artemis expression at levels that are nontoxic yet sufficient to correct the T(-)B(-) phenotype, crucial for preclinical studies and clinical application of Artemis gene transfer in the treatment of human SCID-A.
Artemis 是一种发夹状核酸内切酶,参与非同源末端连接和 V(D)J 重组。Artemis 缺陷导致辐射敏感的严重联合免疫缺陷 (SCID),其特征是由于受体重组阶段停滞而完全缺乏 T 和 B 细胞。我们已经生成了几种用于转导 Artemis 序列的慢病毒载体,旨在补充缺陷表型。我们发现,由强 EF-1alpha 启动子调控 Artemis 的慢病毒载体转导会导致细胞活力的剂量依赖性丧失,这是由于细胞周期分布失调、DNA 损伤增加和凋亡细胞频率增加所致。在暴露于相同数量的对照载体的培养物中未观察到这种毒性反应。用 Artemis 表达构建体转染的细胞也观察到细胞活力丧失,表明毒性与慢病毒转导无关。当用中等强度的磷酸甘油酸激酶启动子调节 Artemis 表达转导细胞时,观察到毒性降低。这些结果在建立支持 Artemis 表达的条件方面提出了新的挑战,这些条件的毒性水平既非毒性又足以纠正 T(-)B(-)表型,这对于 Artemis 基因转移的临床前研究和临床应用至关重要,可用于治疗人类 SCID-A。